Restoration of Central Vision With PRIMA in Patients With Photoreceptor Degeneration

Key facts

Sponsor

Science Corporation

Intervention

PRIMA Products(device)

Enrollment

5 enrolled

Eligibility

18 years · All sexes

Timeline

2025 – 2031

Study locations (1)

• Sydney Eye Hospital, Sydney, New South Wales, Australia

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Retinitis pigmentosa

Additional recruiting or active studies for the same condition.

• RECRUITINGNCT07502664
  Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherited Retinal Disease (DEFINE-IRD)
  Ray Therapeutics, Inc.
• RECRUITINGNANCT07292987
  Implementation and Evaluation of a Post-Diagnostic Announcement Protocol at the CRMR RefeRet, Quinze-Vingts Hospital
  Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts
• RECRUITINGNCT07228793
  Natural History Study of Patients With EYS-Associated RP
  Sensor Technology for Deafblind
• RECRUITINGPHASE1, PHASE2NCT06891885
  A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years of Age or Older With Retinitis Pigmentosa
  Sumitomo Pharma America, Inc.
• RECRUITINGPHASE2NCT07174726
  A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis Pigmentosa
  Beacon Therapeutics
• RECRUITINGPHASE2NCT06628947
  A Phase II Study of Intravitreal KIO-301 in Patients With Late-stage Retinitis Pigmentosa
  Kiora Pharmaceuticals, Inc.
• RECRUITINGPHASE2NCT06912633
  Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)
  jCyte, Inc
• RECRUITINGNCT06982417
  InsightRP2 Registry
  University of Göttingen

See all trials for Retinitis pigmentosa →